OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
20 apr 2009 - 18:47
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus' licensee Biolex commences Phase IIb study with Locteron
Bericht
OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has commenced patient dosing in the SELECT-2 Phase IIb clinical study of Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. Locteron combines OctoPlus’ controlled release drug delivery technology PolyActive® with Biolex’ interferon alpha and is the most advanced product in clinical development incorporating one of OctoPlus’ proprietary drug delivery technologies.
Datum laatste update: 20 december 2025